Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001401476 | SCV001603302 | likely benign | not provided | 2025-01-15 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002552731 | SCV003687180 | uncertain significance | Inborn genetic diseases | 2022-09-30 | criteria provided, single submitter | clinical testing | The c.1412T>C (p.F471S) alteration is located in exon 9 (coding exon 9) of the ALDH3A2 gene. This alteration results from a T to C substitution at nucleotide position 1412, causing the phenylalanine (F) at amino acid position 471 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Ce |
RCV001401476 | SCV004142449 | likely benign | not provided | 2022-08-01 | criteria provided, single submitter | clinical testing | ALDH3A2: BP4 |
Mayo Clinic Laboratories, |
RCV001401476 | SCV005412684 | uncertain significance | not provided | 2023-09-25 | criteria provided, single submitter | clinical testing | PM2_moderate |